Eidos Therapeutics, Inc. (EIDX): Price and Financial Metrics
EIDX Price/Volume Stats
| Current price | $122.21 | 52-week high | $132.54 |
| Prev. close | $128.44 | 52-week low | $28.39 |
| Day low | $116.83 | Volume | 335,500 |
| Day high | $128.49 | Avg. volume | 128,113 |
| 50-day MA | $108.40 | Dividend yield | N/A |
| 200-day MA | $65.26 | Market Cap | 4.75B |
EIDX Stock Price Chart Interactive Chart >
Eidos Therapeutics, Inc. (EIDX) Company Bio
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was incorporated in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma LLC.
EIDX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | 103.45% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | 129.27% |
| 2019 | 317.08% |
Loading social stream, please wait...